News Center

Home page

Peak Report

News reports

Announcement of Jianfeng Group Lin2017 -005 on Subsidiary Obtaining Drug Clinical Trial Approval

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviations: Jianfeng Group Number: Pro 2017-005

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Subsidiaries Obtaining Approval for Drug Clinical Trials

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

1. Summary

Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, received the "Drug Clinical Trial Approval Document" (Deoxypodophyllotoxin for Injection, Approval Document No.: 2017L01082 ) and (Deoxypodophyllotoxin, Approval Document No: 2017L01083)(hereinafter collectively referred to as "DPT"). The relevant details are hereby announced as follows:

2. drug basic information content

(I) deoxypodophyllotoxin

drug name: deoxypodophyllotoxin

English name: Deoxypodophyllotoxin

dosage form: bulk drug

application items: domestic Drug Registration

Registration Classification: Chemical Drug Class 1

Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University

Approval Conclusion: "According to the the People's Republic of China Drug Administration Law and relevant regulations, after examination, this product meets the relevant requirements of drug registration and agrees to conduct clinical trials of this product preparation."

(II) deoxypodophyllotoxin for injection

drug name: deoxypodophyllotoxin for injection

English name: Deoxypodophyllotoxin for Injection

dosage form: injection

application items: domestic drug registration

specification: 100mg

registration classification: chemical drugs category 1

applicant: Zhejiang Jianfeng pharmaceutical co., ltd. and China pharmaceutical university

approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, this product meets the relevant requirements of drug registration and agrees to carry out clinical trials."

Research and Development and Registration of 3. Drugs

DPT Project was established in March 104 by 2012. Jianfeng Pharmaceutical Co., Ltd. is a new anti-tumor drug developed in cooperation with China Pharmaceutical University. The registration classification belongs to Class 1 of chemical drugs. The first DPT clinical trial application submitted by Jianfeng Pharmaceutical was accepted on July 27, 2016 (acceptance numbers: CXHL1600201 Zhejiang, CXHL1600202 Zhejiang). DPT is an alkaloid antineoplastic drug with tentative indications for lung cancer, breast cancer and gastric cancer, which will be finalized based on clinical trial results. As of the date of this announcement, the accumulated research and development investment and other related expenditures of the DPT project of Jianfeng Pharmaceutical Co., Ltd. totaled about 34.12 million yuan.

Market Situation of Similar Drugs in 4.

Currently, the same alkaloid anti-tumor drugs listed in China mainly include paclitaxel, vinorelbine and docetaxel. The main manufacturers of paclitaxel injection include Yangzijiang Pharmaceutical Group Co., Ltd., Beijing Shuanglu Pharmaceutical Co., Ltd., Haizheng Pfizer Pharmaceutical Co., Ltd., etc, the main manufacturers of Vinorelbine include Jiangsu Haosen Pharmaceutical Group Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Haizheng Pfizer Pharmaceutical Co., Ltd., etc., and the main manufacturers of docetaxel injection include Jiangsu Hengrui Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd.

According to IMS database statistics, the global sales of the above three drugs in 2015 were 16.46, 1.07 and 0.669 billion US dollars respectively, totaling 2.422 billion US dollars.

5. products still need to go on the market.

DPT is currently in the approved clinical trial stage. Jianfeng Pharmaceutical will complete the clinical trial according to the requirements of the "Drug Clinical Trial Approval". After the clinical trial is completed, it will declare for production. It can only produce and market after passing the review and approval of CFDA and obtaining the drug production approval.

Impact of 6. on Listed Companies and Risk Tips

The company has obtained the "Drug Clinical Trial Approval" this time, which will not have a significant impact on the company's recent operating results.

Due to the particularity of drug research and development, there are unpredictable risks such as long cycle and many links from clinical trials to commissioning. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

March 22, 2017

More information

2022 China's Top 100 Building Materials Enterprises 2022 China's Top 100 Cement Clinker Production Capacity Peak even on two authoritative lists

In March, the authoritative organization of the cement industry successively released two series of lists of China's top 500 building materials enterprises in 2022 and China's top 100 cement clinker production capacity in 2022. Jianfeng Group ranked among the "top 100" in the two lists ". The list of China's top 500 building materials enterprises was officially released in early March. This series of lists was selected by the China Building Materials Enterprise Management Association. Through more than 20 years of comprehensive data research on China's building materials industry, referring to international practices, the rankings are based on the company's annual operating income., Cement products, building ceramics, waterproof materials, aluminum-plastic profiles, coatings, glass, building materials equipment manufacturing and other sub-industries related to building materials. Jianfeng Group ranks 96th among the companies on the list and 27th among the cement manufacturers on the list. On March 16, the awarding ceremony of 2022 China's top 100 cement clinker production capacity list was held in Hangzhou. This series of lists is released by China Cement Network, an authoritative organization in China's cement industry. The ranking is based on the total production capacity (excluding the production capacity of other kiln types and grinding stations) of new dry clinker production lines completed and put into operation by Chinese cement enterprises in China as of December 31, 2022. The data statistics are calculated based on the design production capacity and 310 days of annual operation. Jianfeng Group ranked 53rd with an annual design capacity of 3.627 million tons. (this newspaper reporter)

2023

03-21

Company sends off retired employees

On the morning of February 22, the trade union of the group company held a simple and warm farewell party for retired employees in 2021-2022. More than 50 retired employees gathered together to discuss and exchange with Jiang Xiaomeng and other group leaders.

2023

03-04

On the first day of the new year, group leaders went to the grassroots level.

On January 29, the first day of work after the Spring Festival holiday, the leaders of the group company made a video connection to subordinate enterprises stationed abroad, and separately visited the gold enterprises to learn about the resumption of work and put forward requirements for the implementation of the work plan for the new year.

2023

02-17

Group Companies Commend 2022 Advanced

On the morning of January 18, the group company held the 2022 annual summary commendation meeting to review the work of the previous year, make arrangements for the work in 2023, sign the 2023 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2022 advanced collectives and individuals.

2023

01-29

Jiang Xiaomeng re-elected chairman of the Municipal Federation of Industry and Commerce

On December 24, 2022, the Jinhua Federation of Industry and Commerce (General Chamber of Commerce) held the seventh member representative meeting. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, was re-elected as the chairman of the Municipal Federation of Industry and Commerce at this meeting.

2023

01-12

Peak Pharmaceutical Donates Epidemic Prevention Materials

Since the optimization and adjustment of the new crown infection epidemic management policy, there has been an explosive growth of infected people in the country, and the pressure on the supply of related materials has increased sharply. Before and after New Year's Day, the company has twice organized epidemic prevention materials, through the Jinhua City Charity Federation, Jinhua City Economic and Technological Development Zone Charity Federation targeted donations, a total value of more than 200,000 yuan.

2023

01-12

< 1 2 3 4...61 > 跳转到页